Abstract: Multidrug resistance (MDR) of neoplastic tissues is a major obstacle in cancer chemotherapy. The predominant cause of MDR is the overexpression and drug transport activity of P-glycoprotein (P-gp, a product of the MDR gene). P-gp is a member of the ATP binding cassette (ABC) transporters family, with broad substrate specificity for several substances including anticancer drugs, linear and cyclic peptides, inhibitors of HIV protease, and several other substances.
INTRODUCTION
Multidrug resistance (MDR) of neoplastic cells is a condition in which cells are resistant to unrelated drugs with completely different chemical structures and mechanisms of pharmacological action [1, 2] . It can be acquired or intrinsic, depending on the type of tissue. Acquired MDR is usually a consequence of chemotherapy [3] . In sensitive cells, MDR can develop rapidly and constitutes a serious obstacle in chemotherapy of malignant diseases [4, 5] . Studies of many investigators have identified the MDR mechanisms described below (for review see ref. [2] ):
1.
Activation of detoxification metabolic pathways as a consequence of activation and/or overexpression of against the toxic actions of various chemicals [11] . Overexpression of P-gp in malignant cells is the most frequent cause of MDR [12] . The current review provides a description of function, biochemical characteristics, substrate and inhibitor specificity of P-gp as well as of the cellular mechanisms that may be associated with the development of P-gp mediated MDR.
BIOCHEMICAL CHARACTERIZATION AND FUNC-TIONAL PROPERTIES OF P-GP
P-gp, a transmembrane glycoprotein, was first detected as a surface phosphoglycoprotein overexpressed in cultured cells that developed multidrug resistance [13] , and was subsequently cloned from mouse and human cells [14] [15] [16] [17] . It is a 170 kDa ATP-hydrolyzing drug efflux pump, which is a member of the ABC superfamily of transporters [13] . The glycoprotein can bind and extrude through the plasma membrane an unusually broad, yet well-defined spectrum of structurally unrelated cytotoxic drugs [1, 18] . P-gp can also bind compounds, chemosensitizers, which reverse P-gpmediated multidrug resistance [19, 20] . P-gp is encoded by genes of the ABC transporters multigen family and is a product of mdr1 and mdr2 genes. Analysis of mdr genes revealed a striking sequence homology between P-gp and several bacterial transport proteins [21] . Transfection studies have demonstrated that protein products of the mdr1 and m d r 2 genes (P-gp I and P-gp II isoforms) decrease intracellular concentrations of a wide variety of structurally diverse chemotherapeutic agents, resulting in MDR [17, 22] . In contrast, expression of the mdr3 (designated as mdr2 in humans) gene product does not confer MDR [23, 24] . The mdr1 gene can be up-regulated in response to stress stimuli induced by anti-cancer drugs, phosphatase inhibitors, etc. [25, 26] . Several lines of evidence suggest that regulation occurs at the transcription level by increased activity of the mdr1 promoter region, which contains recognition sites for several transcription factors [27] . On the other hand, no role in multidrug resistance has been identified for the closely related product of the mdr3 gene (the P-gp III isoform) [28] . This isoform of P-gp can function as phosphatidylcholine (PC) translocase, or flippase, responsible for efflux of this phospholipid into bile.
Human P-gp has an apparent molecular mass of 170 kDa and contains 1280 amino acids. It consists of two similar halves of 610 amino acids each, joined by a linker region consisting of 60 charged residues [29] . Each of the two halves is predicted to form six transmembrane spans and hydrolyze ATP during molecular transport. The presence of both halves (including the nucleotide binding sites) is essential for the transport activity [30] . The minimum functional unit for P-gp in membranes appears to be a monomer.
P-gp is subject to several post-translational modifications, such as N-glycosylation and phosphorylation. A recent study has shown that the stability of P-gp is regulated also by ubiquitination [31] . Transfection of MDR cells with a wild-type ubiquitin or treatment with an Nglycosylation inhibitor increased both ubiqutination of P-gp and P-gp degradation. This indicates a role of the ubiquitinproteosome pathway in modulation of P-gp-mediated drug resistance; modulation of P-gp by ubiquitination can be a novel approach to reversal of multidrug resistance [31] .
The original function attributed to P-gp was the drug efflux function in MDR. P-gp is expressed in numerous human tissues as well as in a large number of cancers. The distribution of P-gp on the luminal surfaces of normal tissues including renal tubules, colon, small intestine, and bile canaliculi is consistent with its proposed role in excretory transport. P-gp is present also in the brain capillaries that form the blood-brain barrier [32] . It is localized in the lining endothelium where it can restrict entry of lipophilic drugs into the brain and export substances, such as β-amyloid, from the neuroparenchyma [33] . This could have important consequences for the course of Alzheimer's disease pathology. An inverse correlation between cerebrovascular P-gp expression and deposition of β-amyloid in aged human brains has been demonstrated [34] . It was also demonstrated that P-glycoprotein decreases brain accumulation of several drugs (colchicines, vinblastine, doxorubicin, and morphine) in mdr1a deficient mice [35] . Pgp limits the penetration of HIV protease inhibitors indinavir, nelfinavir, and saquinavir into the brain [36] . In the rat brain, endothelial cells increase P-gp levels upon exposure to H 2 O 2 and inhibition of this effect by LY294002, an inhibitor of the PI3K/Akt kinase pathway, was documented [37] . This suggests that increased P-gp levels can also protect cells against ROS-induced apoptosis [37, 38] .
FUNCTIONAL AND STRUCTURAL CHANGES IN THE DEVELOPMENT OF P-GP MEDIATED MDR
Exposure of cells to the selection pressure of cytotoxic drugs leads to the development of drug resistance. Under these conditions, several changes in cell structure and metabolism can be observed. These changes may be related either to systems directly involved in MDR development (overexpression of drug transporters like P-gp, MRP, enzymes involved in glutathione detoxification systems, or down-regulation of topoisomerase isoenzymes [7, 9] ), or to MDR supporting mechanisms. The latter comprise a broad scale of phenotypes involving acceleration of respiration and ATP production [39] [40] [41] [42] , formation of intracellular compartments for drug accumulation in caveolae and vesicles [43, 44] , changes in intracellular signaling mediated by protein kinases [45, 46] , calcium [47] , calcium binding proteins [48] [49] [50] [51] , and others.
Elevated glucosylceramide synthase activity was reported to also be associated with the P-gp-mediated MDR phenotype [52] . On the other hand, some authors suggest that P-gp-mediated MDR does not depend on ceramide formation [53] or glycosylation [54] . Reynolds and coauthors [55] have drawn attention to the fact that the MDR phenotype could involve a decreased level of ceramideinduced apoptosis because of the production of glucosylceramide, which is an ineffective product of the ceramide pathway in induction of apoptosis. The role of this phenomenon is unclear, because other authors found that inhibition of glucosylceramide synthase does not reverse drug resistance in cancer cells [56] .
The anti-tuberculosis drug rifampin was shown to induce expression of P-gp and cytochrome P450 mRNA in human mononuclear cells probably under control of pregnane X receptor (PXR) [57] . Moreover, PXR was found to mediate P-gp expression in human colon carcinoma cells LS174T via the nuclear receptor responsive elements in the mdr1 gene promoter [58] . A positive correlation between PRX and P-gp mRNA level in peripheral blood mononuclear cells was also reported recently [59] . Correlations between PRX and cytochromes P450 CYP3A4 and CYP2B6 [60] , but not between PRX and P-gp [61] were observed in the liver. These data indicate that PRX-modulated coexpression of cytochrome P450 isoenzymes and P-gp is tissue specific.
Numerous changes in cell structure and metabolism associated with P-gp-mediated MDR phenotype are often observable only in cells adapted to chemotherapeutic agents and could not be found in cell models with a stable transfection of P-gp. If present in both types of cells, they may be considered as changes involved in modulation of expression and/or transport activity of P-gp. The cascade involving extracellular-signal regulated protein kinases (ERKs) could serve as an example. It was found that in ovarian cell lines with a stable expression of mdr1 cDNA, the development of drug resistance was connected with activation of ERKs [62] . Inhibition of this pathway using specific inhibitors reversed the drug resistance. Similar effects were also observed in multidrug resistant cells obtained by adaptation to cytostatic drugs [63] . On the other hand, co-expression of caveolin and caveolae with P-gp was found only in cells obtained by drug selection method [43, 44, 64] . This suggests that this factor is not directly related to the function and expression of P-gp in multidrug resistant cells. These examples show that studies on cells with stable transfection of P-gp cannot provide comprehensive information about all mechanisms involved in P-gpmediated MDR. On the other hand, information received by comparison of data from both types of cells may provide a more precise view of the mechanisms of MDR phenotype.
Phosphorylation and Protein Kinases
The development of multidrug resistance associated with overexpression of P-gp can be accompanied by changes in expression of other proteins, in particular, protein kinases. It is known that P-gp contains sites with structural features mimicking phosphorylation sites for protein kinases such as protein kinase C (PKC) or protein kinase A (PKA) [65] . Moreover, P-gp is also phosphorylated in vivo and the linker region (amino acids 629-686) was identified to be the major phosphorylation domain [66] . It has been shown that substitution of PKA and PKC phosphorylatable residues in the P-gp linker region affects the stimulation of P-gp ATPase activity by some (but not all) substrates [67] . Moreover, it was shown in another study that phosphorylation of the minilinker domain (MLD) of P-gp affects the function of the nucleotide binding domain 1 (NBD1) [68] . The role of phosphorylation in modulation of P-gp function was documented also by Zhan et al. [69] . They found that PKCalpha phosphorylates and activates P-gp, and inhibition of this kinase by p53 led to a decreased P-gp phosphorylation in soft tissue carcinoma cells and thus sensitized these cells to chemotherapeutic agents. Chaudhary and Roninson [70] showed that activation of PKC by diacylglycerol or 12-Otetradecanoylphorbol-13-acetate increased the expression of P-gp at the mRNA and protein levels. PKC412, a staurosporine derivative that is a more selective inhibitor of conventional PKC isoforms, reversed the drug efflux function of P-gp in cell samples from patients with B-cell chronic lymphocytic leukemia in a dose dependent manner [71] . A significant correlation between P-gp expression and the reversal of drug efflux activity by both verapamil and PKC412 have been observed as well.
In several cancer cell types, expression of P-gp was found to go in parallel with activation and/or expression of mitogen-activated protein kinases (MAPKs), PKC, and Akt kinase; these protein kinase pathways have been reported to modulate the expression of human or rat mdr1 genes and Pgp transport activity in some multidrug resistant cell types [37, 45, 46, 63, 65, 72, 73] . In ovarian cancer cell lines, a crosstalk between the ERK (extracellular-signal regulated kinase) signaling pathway and P-gp was assumed [62] . Stable expression of the mdr1 gene generated highly taxolresistant sublines with activated ERK [62] , and inhibition of this cascade by specific inhibitors (UO126, PD098059) significantly re-sensitized the resistant cells. We have found similar effects of both ERK inhibitors on P-gp-mediated multidrug resistance also in a cell line prepared by adaptation to vincristine [63] . The susceptibility of cancer (tumor) cells to apoptosis induced by chemotherapeutic drugs depends on the balance between important proapoptotic and anti-apoptotic (survival) signals. The ERK and PI3K/Akt kinase cascades are known as important survival cell signaling pathways, and inhibition of these systems may be crucial for effective cancer chemotherapy., The role of the Raf/MEK/ERK pathway in regulation of P-gp expression has been described in several studies [74, 75] . Moreover, Raf-1 activation led to increased expression of Pgp in MCF-7/Bcl-2 cells, and cells overexpressing constitutively active ∆Raf-1 showed higher levels of both Pgp mRNA and protein, as well as resistance to doxorubicin [76] . The effect of a specific inhibitor of PI3K/Akt kinase pathway (LY294002) [37] as a P-gp reversal agent suggests a role of this phosphorylation cascade in P-gp mediated MDR. In human hepatoma and embryonic fibroblast 293 cells, 2-acetylaminofluorene (2-AAF) induced the activation of the mdr1 gene and this was accompanied by activation of the PI3 kinase (PI3K) pathway [72] . Using a transfection assay, it was also demonstrated that constitutively activated PI3K and Rac1 (downstream effector of PI3K) enhanced the activation of the mdr1 promoter by 2-AAF [72] . These results suggest that the up-regulation of mdr1 expression is mediated by effectors of the PI3K/Akt pathway.
As suggested by several lines of evidence, an important role in the connection between MAPK and P-gp may be played by the hypoxia-inducible factor (HIF)1-α that was found to control mdr1 gene expression. A tight cooperation between HIF and MAPKs in the mechanism of regulation of P-gp expression has been described by Wartenberg et al. [77] . On the other hand, expression of both P-gp and HIF was found to be regulated by the intracellular redox state [78] . Consequently, P-gp expression may also be influenced by reactive oxygen species. In a recent study, an increased expression of P-gp by a signaling pathway involving reactive oxygen species, p38-MAPK and HIF, was reported [77] . Glycosylation P-gp is synthesised as a 140 kDa precursor and processed via N-linked glycosylation [30, 79] to the final 170 kDa transmembrane glycoprotein. The glycosylation of P-gp isoforms seems to be tissue specific, with differences in molecular size of P-gp from human kidney, liver, adrenal, and a MDR KB cell line [79] . These data indicate alterations in N-glycosylation of P-gp in normal and tumor cells. However, several lines of evidence suggest that changes in glycosylation of P-gp are not essential for manifestation of its transport activity. Mutants of MDR cell lines with significantly reduced ability of cell surface glycosylation as well as cell lines grown in the presence of glycosylation inhibitor, tunicamycin, did not show changes in transport properties of P-gp [18, 30] .
The structure of sugar moieties of P-gp is related to the properties of the membrane in which the P-gp will be incorporated, because carbohydrate chains are believed to take part in correct protein folding [80] . Consistent with this is the finding that a SDS-soluble P-gp isoform, but not a non-ionic detergent-soluble isoform, exhibits high affinity towards tomato lectin [80] . This indicates that the SDSsoluble P-gp glycoform contains polylactosamines in its polysaccharide chain. However, the precise function of these oligosaccharide chains is not fully understood. Besides P-gp glycosylation, also glycosylation of other substances including proteins may have important roles in P-gpmediated MDR, as documented by hypersensitivity of the multidrug resistant KB-C1 cell line to inhibitors of glycosylation (tunicamycin, 2-deoxy-D-glucose) [81, 82] . The latter finding indicates that overexpression of P-gp may be associated with changes in metabolism of sugars and energy production [83] . Consistent with this notion, we have observed dramatically reduced levels of UDP sugars in the L1210/VCR multidrug resistant cell line compared to parental sensitive cells [84] . This was associated with reduced levels of glycogen and sialic acid on the external cell coat as well as with decreased content of glycoproteins bound to ConA-Sepharose. The development of vincristinecolchicine resistance of L1210 cells is associated with strong differences in sugar structure of external cell membrane, as can be deduced from the fact that ConA more extensively agglutinated the sensitive than the resistant cell line [85] . In our experiments [84] , L1210/VCR cells were less sensitive to ConA as parental cells. This could be simply explained by the assumption that the cell surface of resistant cells contains lower amount of saccharides than is the case in sensitive cells. Thus, ConA would less effectively cross-link and consequently affect the viability of resistant cells compared to sensitive cells.
Structural Changes
Structural and ultrastructural characteristics of multidrug resistant neoplastic cells expressing P-gp are typical for cells engaged in a metabolically demanding process of protein synthesis and transport. However, published observations related to differences in ultrastructure between sensitive and resistant cell lines are relatively sparse. Morphological analysis of adriamycin-resistant human K562 leukaemic cells has shown that the resistant cell line can be discriminated from its parental drug-sensitive counterpart by the appearance of electron opaque vesicles and by changes in nuclear and cell surface topography [86, 87] . In Syrian hamster embryo fibroblasts transformed by the Rous sarcoma virus rendered resistant by cultivation in a colchicine-supplemented medium, significant alterations of cytoskeletal elements and vacuolar system, e.g. changes in actin stress-fibre organization, microtubule distribution, the Golgi complex structure and vesicular transport have been described [88] . In the same cell lines, differences in the effect of Brefeldin A, blocker of vesicular transport, on Golgi apparatus and vesicular transport in sensitive and resistant cells could be observed [89] .
The increased demand on energetic and nutritional resources in resistant cells due to P-gp overexpression and drug extrusion manifest themselves in increased cell size. We have measured [90] the diameter of sensitive and resistant L1210 cells and have found that the mean cell diameter has increased two to three times. Ultrastructurally, this increase may be accounted for by increased density of ribosomes with their aggregation into tetrameres and pentameres, more extensive Golgi apparatus, more numerous mitochondria, and by appearance of vacuoles in the cytoplasm (El-Saggan, Uhrík and Breier, unpublished observations). The decrease in surface-to-volume ratio due to increased cell size in resistant cells is compensated (at least partly) by proliferation of villous projections and cytoplasmic protrusions of the cell surface. The highly corrugated cell membrane efficiently increases the area necessary for drug extrusion via P-gp transporters [40, 84] . Another characteristic change on the surface of resistant L1210 cells was a decreased stainability of external lamina with the polycationic dye ruthenium red, reflecting a lower amount of saccharides and, in particular, of sialic acid [84] .
Nuclear morphological alterations with changes in chromatin texture have been described in multidrug-resistant human leukaemic cell lines obtained via selection by cytotoxic drugs [91, 92] . Similar changes have also been found in multidrug-resistant human ovarian and lung carcinoma cells. The textural differences with chromatin decondensation were assumed to be correlated with gene expression [93, 94] .
In some resistant cells grown in the presence of drugs, an increased number of vacuoles and vesicles could be observed in the vicinity of the cell membrane. These vesicles may be an additional way of decreasing the cellular uptake of drugs in multidrug resistant cells. Anticancer drugs could accumulate in the vesicles and an increased rate of exocytosis could contribute to expulsion of the drugs from cells (for reviews, see refs. [4, 95] ). There are several reports showing the sequestration of antitumor drugs into vesicles in various neoplastic cell lines. For instance, the shift of antitumor drug fluorescence from the cytoplasm and nucleus in sensitive parental cells to cytoplasmic perinuclear vesicles in MDR cells, the shift being reversed by certain drugs that reverse MDR, such as verapamil [96] [97] [98] [99] [100] [101] [102] [103] [104] .
Immunocytochemical studies on different drug resistant neoplastic cell lines performed at the light and electron microscopic levels have demonstrated the presence of Pglycoprotein not only at the plasma membrane but also on the membranes of intracellular organelles, predominantly vesicles of the Golgi and the lysosomal systems [105] [106] [107] [108] . Another intracellular site where P-glycoprotein has been detected is the nuclear envelope of multidrug resistant cells [109] .
In several multidrug-resistant tumour cell lines, there is a dramatic increase in the number of caveolae and in the level of caveolin-1 [43, 44] . In contrast, we found caveolae neither in L1210/VCR resistant cells nor in parental cells (ElSaggan, Uhrík and Breier, unpublished results). Fra et al. [110] have found that there are no caveolae in lymphocytes, but there are detergent-insoluble glycosphingolipid-enriched complexes (DIGs) and detergent insolubility does not correlate with the presence of caveolae or of caveolin. In spite of the absence of caveolae in L1210 cells, DIGs, related to lipid rafts (sphingolipid-and cholesterol-rich microdomains; for a review, see Hooper [111] ) may be present also in this cell line, as suggested by Fan et al. [112] .
Differences in localization of mitochondria between sensitive and resistant tumor cells, as seen by laser scanning confocal microscopy, have recently been described by Villa and Doglia [113] . In the sensitive MCF-7 cell line (derived from epithelial breast cancer), active mitochondria were found in the perinuclear region, whereas in the MDR subline (MCF7/DX) they were confined to the cell periphery. The MDR revertant verapamil has been found to restore in MCF-7/DX cells the same pattern of active mitochondria as that seen in sensitive cells.
SUBSTRATE SPECIFICITY OF P-GLYCOPROTEIN AND RELATION BETWEEN SUBSTRATE STRUC-TURE AND ITS AFFINITY TO THE DRUG BINDING SITE
A large and diverse group of structurally unrelated substances may act as P-gp substrates (for a review, see refs. [2, 12] ). The group includes anthracyclines (e.g. doxorubicin), vinca alkaloids (e.g. vincristine), actinomycines (e.g. actinomycin D, dactinomycines), taxols (e.g. paclitaxel), alkylating agents (mytomycin C), peptide antibiotics (gramicidin, valinomycin), and many others. HIV-1 protease inhibitors can be considered as P-gp substrates and thus P-gp might negatively influence the treatment of HIV patients with these substances [114, 115] . On the other hand, P-gp is able to effectively extrude the viral gp41 hydrophobic peptide from cells. Interaction of this peptide with the cell plasma membrane is an initial step in HIV-1 entry into the cells. P-gp may decrease HIV-1 infectivity in a P-gp expressing cell line [116] . From this point of view, P-gp is an ABC transporter with extremely broad substrate specificity [117] .
Several fluorescent P-gp substrates, such as doxorubicin [118] [119] [120] [121] or rhodamine 123 [118, 122] have been used for demonstration of P-gp transport activity. Intracellular calcium indicators, such as calcein [123, 124] , fura-2 [120, 125] and fluo-3 [126] , in particular their esterified forms (in which they are able to enter cells via passive diffusion through plasma membrane) are substrates for P-gp and may be used for precise measurement of P-gp transport activity using flow cytometry or confocal microscopy.
The extreme structural diversity of P-gp substrates poses an enigma regarding the structure and mode of function of the P-gp drug-binding site that has to be resolved. To bind and transport several unrelated substances, P-gp should contain site(s) able to bind compounds characterized by a molecular weight of several hundreds that contain hydrophobic and/or basic moieties [127, 128] . We have proposed [129] that for recognition at P-gp binding sites, a substrate should possess the following characteristic features: (i) flexible structure giving rise to different structural conformers; (ii) molecular weight lower than 1300 g/mol; (iii) deprotonized character at neutral pH. A relatively high hydrophobicity and molecular size and also existence of at least one tertiary basic nitrogen atom on the drug molecule were found to be important for drug interaction with P-gp [130] . The latter authors did not differentiate carefully between P-gp substrates and modulators. However, it may be considered reasonable because several P-gp substrates can be recognized also as P-gp inhibitors, i.e. MDR overcoming and/or reversal agents [12] . This phenomenon is one of the four confusions described by Didziapetris et al. [131] in their attempt to classify P-gp substrates. The authors proposed the following criteria for a substance to be a P-gp substrate: (i) sum of nitrogen and oxygen atoms in the molecule should exceed 8; (ii) molecular weight should exceed 400; (iii) acid pK a should exceed 4. A multiplepharmacophore model that can discriminate between a P-gp substrate and "nonsubstrate" with accuracy of 63 % was described by Penzotti et al. [132] . In spite of the relatively low prediction confidence, this model could be a useful application filter allowing identification of P-gp substrates in a large library of compounds. All features of P-gp substrates described by the authors quoted above could be considered only as empiric criteria and causal mechanisms of P-gp substrate binding and consequent transport have yet to be resolved. Drug binding sites that are able to recognize substances with different chemical structures may have a complex architecture in which different parts are responsible for binding of different drugs. This is also supported by the results of a site directed mutagenesis study of the transmembrane domain 6 of P-gp [133] : (i) replacement of valine 338 by alanine resulted in a mutant P-gp with enhanced resistance to colchicine and reduced resistance to vinblastine; (ii) replacement of glycine 341 by valine resulted in mutant P-gp with reduced resistance to colchicine or doxorubicin, but remaining resistance to vinblastine or actinomycin D; (iii) replacement of alanine 342 by leucine resulted in mutant P-gp with reduced resistance to all four drugs; (iv) replacement of serine 344 by alanine, threonine, cysteine, or tyrosine resulted in mutant P-gp unable to confer drug resistance. This study indicated that drug binding sites of P-gp are localized at least partially in its transmembrane domains. Several other authors described modulation of drug efflux capacity of mutant P-gp after site directed mutagenesis of an amino acid in the transmembrane domains, e.g. histidine 61 in domain 1 [134] , single serines replacements by phenylalanines in transmembrane domain 11 [135] , leucine 975, valine 981 and phenylalanine 983 by alanine in transmembrane domain 12 [136] . A study of cystein scanning mutagenesis and oxidative cross-linking of transmembrane segments revealed that packing of transmembrane segments to the drug binding site is changed when P-gp binds to a particular substrate, indicating the "substrate-induced fit" mechanism [137] .
These findings are consistent with the finding that several small molecules enhance the drug binding activity of P-gp dramatically via modulation of substrate specificity [138] . Using radioligand binding techniques, Martin et al. [139] have shown that at least four drug binding loci should exist on a P-gp molecule. These sites fall into two categories: transport (at which, following drug binding, transport through membrane occurs) and regulatory, which modulate P-gp function. The authors propose for P-gp a "multiple site transition model" based on existence of complex binding sites formed by two independent, spatially distinct but interacting ligand-binding sites for drugs. These two sites may exist in high-and low-affinity configuration for their ligands. Binding of a ligand to the corresponding site modulates affinity of the other site to its substrate.
A pharmacophore-based model was described for P-gp substrates [140] and inhibitors [141] [142] [143] [144] . The pharmacophores have to contain parts with hydrophobic and aromatic characters and functional groups that can act as hydrogen-bond donors and/or acceptors [145] . Ligandbinding regions of P-glycoprotein were identified by activated-pharmacophore photoaffinity labeling [144] . In this study, fragments in putative transmembrane regions 3, 5, 6, 8, 10, 11 and 12 were preferentially labeled by propanephenone type ligands. Labels were also found in the highly charged regions of 15 amino acids located in the EAA-like motif of the second cytoplasmic loop. Moreover, the cytoplasmic loop and cytoplasmic part between transmembrane domain 12 and N-terminus of the Walker A sequence of the nucleotide binding domain 2 were also labeled.
Reversal of P-Glycoprotein-Mediated Multidrug Resistance
A characteristic property of the P-gp-mediated multidrug resistance is its reversal by several non-cytotoxic drugs and substances. From this point of view, verapamil and cyclosporine A are generally accepted as standard inhibitors of P-gp, as well as P-gp-mediated MDR reversal agents. Pgp inhibitory agents (in literature often termed overcoming agents or chemosensitizers) are a group of diverse, yet well characterized substances including calcium and sodium channel blockers, calmodulin antagonists, local anaesthetics, steroidal and structurally related compounds, immunosupressive agents, protein kinase inhibitors, flavonoids, detergents, indole alkaloids, macrolide compounds, methylxanthines derived from pentoxifylline, etc. [12, 19, 20, 46, 63, 119, 121, [146] [147] [148] [149] [150] [151] [152] [153] . As reversers of P-gp-mediated MDR, these substances may act by different mechanisms: (i) direct interaction with the P-gp molecule at its ATP-binding site, drug binding sites or other loci that are critical for its transport function; (ii) modulation of expression of mdr genes encoding P-gp; (iii) modulation of P-gp activity by inhibition of its post-translational modifications (phosphorylation or glycosylation); (iv) indirect modulation of P-gp transport activities by other systems.
Flavonoids, which may be natural products or synthetic compounds, are a special case as they may act directly on Pgp by influencing both the vicinal ATP-and the steroidbinding site [149, 154] . Moreover, as scavengers of reactive oxygen species, they may act by influencing redox states [77, 78] . Natural flavonoids can be supplied to the body as nutrition products. Typical examples are fruit juices [155] , in particular, grapefruit juice [156] , or green tea [157] .
Direct Interaction with the P-gp Molecule P-gp mediates drug transport utilizing energy provided by ATP hydrolysis. From this point of view, a logical approach to inhibition of P-gp activity is the blockade of ATP-binding/hydrolyzing sites of the molecule. Adenine nucleotide analogs, -SH blockers, or vanadate have been studied as inhibitors of P-gp ATP-ase activity [158] [159] [160] . Dietary isothiocyanates that are not transported by P-gp inhibit its transport activity probably by blocking the sulfhydryl group(s) in (or in the vicinity of) the ATP binding site [161] . Several other substances expected to act by different mechanisms were in the end found to reverse Pgp-mediated MDR through direct interaction with ATPbinding sites. Protein kinase C inhibitors, primarily believed to act on P-gp-mediated MDR only through inhibition of PKC-mediated phosphorylation, are a typical example: these substances were found to block P-gp ATPase activity directly [162] . Photoaffinity studies using [ 3 H]-azidopine as a specific P-gp label and P-gp binding studies showed that some PKC inhibitors could interact directly with P-gp. It should be stressed that inhibitors of different protein kinase cascades, such as MAPK, PI3K/Akt and others that were described to reverse P-gp-mediated MDR [46, 63] may possibly also act directly at the P-gp ATP-or drug binding sites.
Modulation of P-gp Activity by Inhibition of its PostTranslational Modifications
Several approaches were used in the study of the role of protein phosphorylation in modulation of P-glycoproteinmediated multidrug resistance. One sought for correlation between changes in both expression and/or activities of distinct protein kinases and P-gp function. Another approach is based on application of specific inhibitors of kinase pathways and their effects on MDR, but their mechanisms of influence on P-gp function is not fully understood. However, several lines of evidence suggest the role of posttranslational modifications, especially phosphorylation, in modulating P-gp transporter activity. These have already been discussed extensively in the section "Functional and structural changes in the development of P-gp mediated MDR -Phosphorylation and protein kinases".
The importance of PKC-mediated protein phosphorylation for P-gp drug efflux activity can be seen from the effect of PKC stimulators (phorbol esters) that were found to elevate P-gp drug transport activity [163] or P-gp expression at mRNA and protein levels [70, 75] . However, in contrast to these findings, other studies have shown that mutation of amino acids in PKC-phosphorylation sites on P-gp did not influence the transport activity of P-gp [164] . Several inhibitors of protein kinases were found to influence P-gp function, but the mechanisms of their action are rather unclear. These substances are originally known to inhibit kinase-mediated phosphorylation but the binding properties and characteristics of P-gp suggest that some of these kinase inhibitors may modulate P-gp function also by direct interaction with the P-gp drug-and/or ATP-binding sites. Moreover, several lines of evidence indicate that kinase inhibitors may also modulate P-gp expression.
All these facts show that, in general, it may be difficult to determine the sequence of events following action of kinase inhibitors and to identify the principal mechanism of action. A parallel involvement of several modes of action also cannot be ruled out.
Modulation of P-gp Expression
In our recent studies, we have found that pentoxifylline, which was able to reverse the P-gp-mediated multidrug resistance in L1210/VCR cells [147, 165] , induced a decrease in the mdr1 gene mRNA expression [121] . In a quantitative structure-activity relationship (QSAR) study, we have described structural criteria that are important for a pentoxifylline analogue to be a P-gp reversal agent [153] . This shows that inhibition of P-gp efflux activity may also be influenced by reduction of cellular P-gp content via down-regulation of mdr1 gene expression. The ability to reduce the levels of mdr1 mRNA was described also for some other chemosensitizers (verapamil and barnidipine) [166] . The mechanisms by which these substances suppress P-gp expression are not yet resolved.
Yang et al. [167] used a model of NIH 3T3 cells transfected with phospholipase C-γ1 expression vector to study the role of PLC and PKC in regulation of mdr1 expression. Augmentation of PLC-γ1 signaling led to activation of the PKC and mdr1 promoters. Activation of mdr1 promoter activity was observable also after action of platelet-derived growth factor (PDGF), an activator of PLCmediated signaling. This PDGF-mediated activation of mdr1 promoter activity was inhibited by PD098059, an inhibitor of the ERK pathway. Inhibition of P-gp expression by PD098059 was documented also by Chen et al. [73] . Another inhibitor of the ERK pathway, UO126, which acts specifically at the MEK level, abrogated the heat-shock induced increase in mdr1 mRNA in HTB-46 cells [167] .
Indirect Ways of Reversal of P-gp Mediated Multidrug Resistance
The function and expression of P-gp can be affected indirectly by several metabolic pathways and some of them are described below. The possibility that P-gp drug efflux activity may be regulated by cyclooxygenase-2 (COX-2) has recently been reviewed by Sorokin [168] . Application of COX-2 inhibitors has often induced a decrease in tissue resistance to chemotherapeutics and mdr1 gene expression with increased accumulation of intracellular therapeutics [169, 170] .
Hypoxic conditions, hyperthermia, and reactive oxygen species formation, which are associated with increased HIF-1α expression, were described to influence the expression and transport function of P-gp [77, 78, 171] . In relation to tissue origin, the HIF-1α action may be dependent or independent on carbonic anhydrase IX expression, which is directly controlled by the hypoxia-responsive element [172] . P-gp transport activity is strictly dependent on energetic metabolism and ATP formation. Thus, the function of mitochondria as well as ATP forming enzyme pathways in the cytosol have to be also listed as mechanisms involved in P-gp-mediated MDR. 
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